Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01714713
Other study ID # EVP-6124-017
Secondary ID 2012-003228-19
Status Completed
Phase Phase 3
First received October 19, 2012
Last updated May 2, 2016
Start date June 2013
Est. completion date October 2015

Study information

Verified date September 2015
Source FORUM Pharmaceuticals Inc
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationGermany: Federal Institute for Drugs and Medical DevicesArgentina: Ministry of HealthAustralia: National Health and Medical Research CouncilCanada: Health CanadaColombia: National Institutes of HealthItaly: National Monitoring Centre for Clinical Trials - Ministry of HealthMexico: Ministry of HealthRomania: National Agency for Medicines and Medical DevicesRussia: Pharmacological Committee, Ministry of HealthSingapore: Singapore Clinical Research InstituteSpain: Ministry of HealthUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyUkraine: State Pharmacological Center - Ministry of HealthBrazil: Ministry of HealthPoland: Ministry of HealthSerbia: Medicines and Medical Devices Agency
Study type Interventional

Clinical Trial Summary

This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies EVP-6124-015 and EVP-6124-016.


Recruitment information / eligibility

Status Completed
Enrollment 830
Est. completion date October 2015
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Completion of the Day 182 visit in a previous 26-week double-blind study (EVP-6124-015 or EVP-6124-016).

- Subject has signed informed consent for this extension study, indicating that the subject understands the purpose of and procedures required for the study, before the initiation of any extension study specific procedures. Subjects who are unable to provide informed consent will not be included in the study

- No clinically significant changes in the subject's medical status during the participation in EVP-6124-015 or EVP-6124-016. Any significant changes in health care status and their impact on subject eligibility will be reviewed by the investigator and sponsor on a case-by-case basis.

- In the opinion of the investigator, the extension treatment is in the best interest of the subject.

- Fertile, sexually active subjects (men and women) must use an effective method of contraception during the study. Females and the female partners of male must be surgically sterile (hysterectomy or bilateral tubal ligation), postmenopausal for at least 1 year, willing to practice adequate methods of contraception if of childbearing potential (defined as consistent use of combined effective methods of contraception [including at least one barrier method]). Female subjects must have a negative urine pregnancy test predose on Day 1.

Exclusion Criteria:

- Significant risk for suicidal or violent behavior, as determined by the investigator. Significant risk for suicidal behavior is defined as 1) suicidal ideation as endorsed on items 4 and 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS); 2) suicidal behaviors detected by the C-SSRS; or 3) psychiatric interview and examination.

- Adverse events from the previous study (EVP-6124-015 or EVP-6124-016) that have not resolved, are of moderate or greater severity and judged to be possibly related or related to study drug and are thought by the investigator to be contraindications to study participation.

- Any condition which would make the subject, in the opinion of the investigator, unsuitable for the study.

- Female subjects who are pregnant.

- Subjects who received any other investigational treatment during participation in either EVP-6124-015 or EVP-6124-016 other than assigned study medication.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
EVP-6124
Arm 1, 2

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
FORUM Pharmaceuticals Inc INC Research

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Belgium,  Canada,  Colombia,  Germany,  Italy,  Mexico,  Poland,  Romania,  Russian Federation,  Singapore,  Spain,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and Tolerability of EVP-6124 or Placebo in Subjects with Schizophrenia All adverse experiences spontaneously reported by subject and/or observed by investigator and repeated clinical evaluation of physical examinations, vital signs, 12-lead ECG (electrocardiogram), ambulatory ECG, and laboratory tests (hematology/blood/chemistry/urinalysis) Baseline through Day 182 or Early Termination Yes
Secondary Change from Baseline in the Clinical Global Impression (CGI) - Severity (CGI-S) to Day 182 Baseline to Day 182 or Early Termination No
Secondary Change from Baseline in the Clinical Global Impression (CGI) - Change (CGI-C) to Day 182 Baseline to Day 182 or Early Termination No
Secondary Change from Baseline in the EuroQol-5D (EQ-5D-5L) to Day 182 Baseline to Day 182 or Early Termination No
Secondary Change from Baseline in the Columbia Suicide Severity Rating Scale (C-SSRS) to Day 182 Baseline to Day 182 or Early Termination No
Secondary Change from Baseline in the Client Socio-Demographic and Service Receipt Inventory-European Version (CSSRI-EU) to Day 182 Baseline to Day 182 or Early Termination No
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A